Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials

被引：0

作者：

Cerqueira, J. ^{[1
]}

Berthele, A. ^{[2
]}

Cree, B. ^{[3
]}

Filippi, M. ^{[4
,5
,6
,7
,8
]}

Pardo, G. ^{[9
]}

Pearson, O. ^{[10
]}

Trabloulsee, A. ^{[11
]}

Ziemssen, T. ^{[12
]}

Vollmer, T. ^{[13
]}

Bernasconi, C. ^{[14
]}

Mandel, C. ^{[15
]}

Overell, J. ^{[14
]}

Havrdova, E. ^{[16
,17
,18
]}

机构：

[1] Univ Minho, Life & Hlth Sci Res Inst, Sch Med, Braga, Portugal

[2] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany

[3] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA

[4] IRCCS San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Milan, Italy

[5] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy

[6] IRCCS San Raffaele Sci Inst, Neurorehabilitat Unit, Milan, Italy

[7] IRCCS San Raffaele Sci Inst, Neurophysiol Serv, Milan, Italy

[8] Univ Vita Salute San Raffaele, Milan, Italy

[9] Oklahoma Med Res Fdn, Multiple Sclerosis Ctr Excellence, Oklahoma City, OK USA

[10] Morriston Hosp, Dept Neurol, Swansea, W Glam, Wales

[11] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada

[12] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany

[13] Univ Colorado Denver, Dept Neurol, Rocky Mt Multiple Sclerosis Ctr, Anschutz Med Campus, Denver, CO USA

[14] F Hoffmann Roche Ltd, Basel, Switzerland

[15] Genentech Inc, San Francisco, CA USA

[16] Gen Univ Hosp, Prague, Czech Republic

[17] Charles Univ Prague, Dept Neurol, Prague, Czech Republic

[18] Charles Univ Prague, Ctr Clin Neurosci, Prague, Czech Republic

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P723

引用

页码：634 / 635

页数：2

共 50 条

[1] Efficacy and safety of ocrelizumab in a treatment-naive, early RMS population: 7-year data from the OPERA OLE trials
Cerqueira, J.
Berthele, A.
Cree, B.
Filippi, M.
Pardo, G.
Pearson, O.
Traboulsee, A.
Ziemssen, T.
Vollmer, T.
Bernasconi, C.
Coulibaly, J.
Mandel, C.
Overell, J.
Havrdova, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 153 - 153
[2] Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS Nine-Year Data From the OPERA Studies Open-Label Extension
Cerqueira, Joao J.
Berthele, Achim
Cree, Bruce A. C.
Filippi, Massimo
Pardo, Gabriel
Pearson, Owen R.
Traboulsee, Anthony
Ziemssen, Tjalf
Vollmer, Timothy
Bernasconi, Corrado
Mandel, Corey R.
Kulyk, Inessa
Chognot, Cathy
Raposo, Catarina
Schneble, Hans-Martin
Thanei, Gian-Andrea
Incera, Elodie
Havrdova, Eva K.
NEUROLOGY, 2025, 104 (04)
[3] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[4] Long-term (>7-year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis
Montalban, X.
Comi, G.
Antel, J.
O'Connor, P.
de Vera, A.
Cremer, M.
Sfikas, N.
Francis, G.
Kappos, L.
JOURNAL OF NEUROLOGY, 2012, 259 : S69 - S70
[5] Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials
Steinman, Lawrence
Comi, Giancarlo
Cree, Bruce A. C.
Bar-Or, Amit
Selmaj, Krzysztof W.
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Huang, Vivian
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
NEUROLOGY, 2019, 92 (15)
[6] Effect of Ocrelizumab on Relapse Rate, and Disability Progression and Improvement in Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled OPERA Trials
Brochet, B.
Hauser, S. L.
Montalban, X.
Naismith, R.
Wolinsky, J. S.
Manfrini, M.
Garas, M.
Julian, L.
Villoslada, P.
Model, F.
Hubeaux, S.
Kappos, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 322 - 322
[7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[8] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[9] Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
Hauser, Stephen L.
Zielman, Ronald
Das Gupta, Ayan
Xi, Jing
Stoneman, Dee
Karlsson, Goeril
Robertson, Derrick
Cohen, Jeffrey A.
Kappos, Ludwig
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (11-12) : 1452 - 1464
[10] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-or, A.
Arnold, D. L.
Hartung, H-P
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Hetzer, J.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474

← 1 2 3 4 5 →